The following articles (labelled with PubMed ID or TBD) are for your review
||Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors.
||Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).
||Icahn School of Medicine at Mount Sinai
||Hit Optimization of 5-Substituted-N-(piperidin-4-ylmethyl)-1H-indazole-3-carboxamides: Potent Glycogen Synthase Kinase-3 (GSK-3) Inhibitors with in Vivo Activity in Model of Mood Disorders.
||Design and synthesis of novel 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine derivatives as selective G-protein-coupled receptor kinase-2 and -5 inhibitors.
||Korea Research Institute of Chemical Technology
||Design, synthesis and efficacy of novel G protein-coupled receptor kinase 2 inhibitors.
||Federico II" University of Naples
||Structure of human G protein-coupled receptor kinase 2 in complex with the kinase inhibitor balanol.
||University of Michigan
||The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
||Georgetown University Medical Center
||Rational design and evaluation of new lead compound structures for selective betaARK1 inhibitors.
||Daiichi Pharmaceutical Co., Ltd.
||(3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
||Merck Research Laboratories